Impact of bleeding and thrombosis on outcome of 945 COVID-19 VV-ECMO cases from a German registry.

Impact of bleeding and thrombosis on outcome of 945 COVID-19 VV-ECMO cases from a German registry.

Publication date: Jun 18, 2025

Bleeding and thromboembolic events (BTE) increase the mortality of COVID-19 acute respiratory distress syndrome (ARDS) treated with extracorporeal membrane oxygenation (ECMO). The current analysis aimed to assess frequency and determinants of BTE according to their location and severity in a retrospective analysis of the German ECMO COVID-19 registry. Logistic regression was applied to identify factors influencing ICU survival as well as variables associated with risks of BTE. In total, 708 of 945 patients (75%) suffered from BTE. Overall, 1,348 events were registered, including 406 (30%) major bleeding and 258 (19%) major thromboembolic events. Most common major bleeding locations were intracranial (n = 133, 10%) and pulmonary bleeding (n = 116, 9%). In-ICU survival was 35, 46% without BTE and 22% with major bleeding (p 

Open Access PDF

Concepts Keywords
German bleeding
Pulmonary COVID-19
Thrombosis extracorporeal membrance oxygenation
thromboembolism

Semantics

Type Source Name
disease MESH bleeding
disease MESH thrombosis
disease MESH COVID-19
disease MESH acute respiratory distress syndrome
disease MESH Emergency
drug DRUGBANK 2′-fluoro-5-ethylarabinosyluracil
disease MESH Hypertension
disease MESH Peripheral Vascular Disease
disease MESH Heart Failure
disease MESH syndrome
disease MESH thromboembolism

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *